Merck Animal Health has announced the FDA’s approval of BRAVECTO (fluralaner) chewable tablets for dogs (112.5 mg, 250 mg, 500 mg, 1000 mg, 1400 mg).  BRAVECTO is the first and only treatment that has been shown to quickly and effectively kill fleas and multiple tick species for 12 weeks in a single dose. BRAVECTO also is effective for eight weeks against Amblyomma americanum ticks.

“BRAVECTO is a breakthrough innovation that offers pet owners and veterinarians something that no other product does – the longest-lasting oral flea and tick prevention currently available,” said KJ Varma, Senior Vice President, Research and Development, Merck Animal Health. “The approval of BRAVECTO is truly a reflection of our 70-year history of innovation, research and commitment to helping shape the future of animal health, as well as our dedication to bringing novel products to market that meet the evolving needs of pet owners, customers and the industry.”